Selective treatment of intracellular bacterial infections using host cell-targeted bioorthogonal nanozymes

Abstract

Intracellular bacterial infections are difficult to treat, and in the case of Salmonella and related infections, can be life threatening. Antibiotic treatments for intracellular infections face challenges including cell penetration...

All-natural gelatin-based bioorthogonal catalysts for efficient eradication of bacterial biofilms

“… 43 The pharmacophore of this antibiotic was blocked through functionalization with a bulky aryl-azide carbamate moiety on its secondary amino group, generating a prodrug (pro-Cip). 44 This caging strategy prevents Cip from binding to its target bacterial enzymes, DNA gyrase and topoisomerase IV, 45 diminishing antimicrobial activity by more than two orders of magnitude (Fig. S4 † ).…”

The recent development of nanozymes for targeting antibacterial, anticancer and antioxidant applications

“…The targeted antibacterial system based on nanozymes mainly includes: aptamers and specic small molecules, such as mannose, C18-PEGn-benzeneboronic acid (CPB), dextran and so on. [12][13][14][15][16] These substances can specically bind with bacteria and then kill bacteria through the catalysis of nanozymes. This part mainly introduces the application of nanozymes with targeting effect in antibacterial system.…”

Bioorthogonal nanozymes: an emerging strategy for disease therapy

“…This bioorthogonal strategy could not only activate pro-antibiotics within the targeted cell, but also could avoid the side effects of antibiotics on the beneficial bacteria in vivo and reduce the occurrence of bacterial resistance. 88 Alternatively, to recognize and capture specific bacteria, Qu and co-workers synthesized the artificial antibody-like bioorthogonal catalysts through bacterial imprinting technology. The designed antibody-like bioorthogonal catalysts had the imprinted matching morphology of the targeted bacteria and could specifically capture bacteria in an antigen-antibody binding manner.…”

“…This bioorthogonal strategy could not only activate pro-antibiotics within the targeted cell, but also could avoid the side effects of antibiotics on the beneficial bacteria in vivo and reduce the occurrence of bacterial resistance. 88…”